Business Activities

Management Plans

Aiming for the advancement of healthcare

The corporate philosophy for the Sysmex Group, the "Sysmex Way," defines its mission as "Shaping the advancement of healthcare." On this basis, we have established a Long-Term Management Goals and a Mid-Term Management Plan aimed at contributing to the advancement of healthcare and a healthy life for people around the world.

Sysmex Group Long-Term Management Goals (2025)

Long-Term Vision

A "Unique & Advanced Healthcare Testing Company"

Positioning

  • Creating innovative diagnostic value as a global top-five company in IVD

    - Aim to become a global top-five company through sustained growth in our core businesses

    - In addition to increasing our share of the IVD market, which continues to grow globally, create new diagnostic value

  • A leading company in personalized diagnostics for optimizing medical treatment

    - Create new testing and diagnostic value that contributes to the selection of treatment methods

    - Fuse our measurement platforms with new technologies and knowledge acquired through open innovation and others

  • A solution provider contributing to the advancement of primary care diagnostics

    - Leverage the diagnostic technologies and IT we have cultivated in the IVD domain

    - Provide solutions that contribute to increased access to healthcare

  • An attractive company providing value and instilling confidence

    - Earn support from diverse stakeholders through distinctive technologies and business model, dynamic human resources and sound and advanced corporate management

  • One Sysmex carrying out high-speed management

    - Provide attractive workplaces where diverse human resources can exercise their talents

    - Make use of sophisticated teamwork to achieve efficient and high-speed management

Sysmex Group Mid-Term Management Plan (Fiscal Years Ending March 31, 2022 to 2024)

Key Actions
  1. Accelerate the introduction of new products aimed at improving growth and profitability, and promote emerging market strategies
  2. Achieve high growth through proactive investment in key fields
    (hemostasis, immunochemistry and life science)
    • - Promote sales in each field through new products
    • - Expand direct sales and service area
  3. Introduce new business to achieve dynamic growth
    • - Use the surgical support robot to develop business in surgical field in Japan and overseas
    • - Create new businesses, such as liquid biopsy*
  4. Promote digitalization in the Group and achieve DX* to create customer value
    • - Transform business processes with a view to strengthening the corporate structure
    • - Reform customer support and create new solutions
  5. Enrich the talent portfolio, which contributes to strategy execution, and create an attractive organizational climate that leverages diverse talent
    • - Encourage entrenchment of the globally consistent job-based human resource management system
    • - Promote diversity and health and productivity management
  6. Formulate a vision and roll out measures to reinforce and implement sustainability management
    • - Promote activities for priority issues (materiality) to realize sustainable growth
  • * Liquid biopsy: Detection of cancer or other diseases by testing blood or other bodily fluids.
  • * DX: Short for "digital transformation," DX refers to enhancing the quality of business and life through digital technologies.

Financial Targets (Fiscal Year Ending March 31, 2024)

Assumed exchange rates during the period of the mid-term management plan:
1USD=¥106.0, 1EUR=¥125.0, 1CNY=¥16.0